US Stock MarketDetailed Quotes
OTLK Outlook Therapeutics
- 2.010
- +0.310+18.24%
Close Dec 27 16:00 ET
- 2.058
- +0.048+2.40%
Post 20:01 ET
47.55MMarket Cap-0.34P/E (TTM)
2.180High1.670Low4.28MVolume1.810Open1.700Pre Close8.40MTurnover30.72%Turnover RatioLossP/E (Static)23.66MShares12.85052wk High-0.57P/B28.02MFloat Cap0.87052wk Low--Dividend TTM13.94MShs Float219.200Historical High--Div YieldTTM30.00%Amplitude0.870Historical Low1.961Avg Price1Lot Size
About Outlook Therapeutics Company
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Company Profile
SymbolOTLK
Company NameOutlook Therapeutics
Listing DateJun 13, 2016
Founded2010
CEOMr. Lawrence A. Kenyon
MarketNASDAQ
Employees24
Fiscal Year Ends09-30
Address111 South Wood Avenue,Unit 100
CityIselin
ProvinceNew Jersey
CountryUnited States of America
Zip Code08830
Phone1-609-619-3990
Company Executives
- Name
- Position
- Salary
- Lawrence A. Kenyon
- Interim Chief Executive Officer, Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Principal Accounting Officer and Director
- --
- Jeff Evanson
- Chief Commercial Officer
- 718.20K
- Ralph H. Thurman
- Executive Chairman of the Board
- 242.50K
- Yezan Munther Haddadin
- Independent Director
- 110.00K
- Andong Huang
- Independent Director
- 75.00K
- Dr. Gerd U. Auffarth, M.D.
- Independent Director
- 79.00K
- Kurt J. Hilzinger
- Independent Director
- 95.00K
- Julian S. Gangolli
- Independent Director
- 112.50K
- Faisal G. Sukhtian
- Independent Director
- 113.00K
- Dr. Julia A. Haller, M.D.
- Independent Director
- 79.00K
Heat List
US
Overall
Symbol
Price
% Chg
No Data
